PHILADELPHIA - FORE Biotherapeutics today announced that the Company will be presenting at the Stifel 2024 Virtual Targeted Oncology Forum.

The virtual presentation will take place on Wednesday, April 17, 2024 at 3:00-3:25 PM ET.

William Hinshaw, Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your Stifel Financial Corporation salesperson or Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company's lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options.

Contact:

Email: moc.srentraptogra@oiBeroF

Tel: 2091.006.212

(C) 2024 Electronic News Publishing, source ENP Newswire